Prothena Corporation plc (PRTA)

NMS – Real vaqt narxi. Valyuta: USD

9.43

-0.24 (-2.48%)

Yopilishda: May 12, 2026, 4:00 PM EDT

9.73

+0.30 (3.18%)

Bozor oldidan: May 13, 2026, 4:08 AM EDT

Umumiy
Yangiliklar
Grafik
Hisobotlar
Dividendlar
Kutilma
Egalik
Profil

Prothena Corporation plc (PRTA)

Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling

Finranks

Kompaniya

Biz bilan bog'lanish

Bizni kuzating

Prothena Corporation plc (PRTA)

Prothena Posts Q1 Earnings as Revenues Surge on Milestone Payment

Prothena Reports First Quarter 2026 Financial Results and Business Highlights

Prothena Announces Novo Nordisk Obtains Fast Track Designation from the U.S. FDA for Coramitug (PRX004) in ATTR Amyloidosis with Cardiomyopathy

Prothena Announces Leadership Team Updates

Wall Street Analysts Think Prothena (PRTA) Could Surge 120.19%: Read This Before Placing a Bet

Prothena Partners Present Data Supporting Next Generation Treatments for Parkinson's and Alzheimer's Disease at AD/PD™ 2026

Prothena Announces Achievement of $50 Million Clinical Milestone Payment from Novo Nordisk Related to Ongoing Phase 3 Clinical Trial for Coramitug (Formerly PRX004) in ATTR Amyloidosis with Cardiomyopathy

Videolar

No Data

Press-relizlar

Prothena Reports First Quarter 2026 Financial Results and Business Highlights

Prothena Announces Novo Nordisk Obtains Fast Track Designation from the U.S. FDA for Coramitug (PRX004) in ATTR Amyloidosis with Cardiomyopathy

Prothena Announces Leadership Team Updates

Prothena Partners Present Data Supporting Next Generation Treatments for Parkinson's and Alzheimer's Disease at AD/PD™ 2026

Search stocks

Prothena Corporation plc (PRTA)

Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling

Finranks

Kompaniya

Biz bilan bog'lanish

Bizni kuzating

Prothena Corporation plc (PRTA)

Prothena Posts Q1 Earnings as Revenues Surge on Milestone Payment

Prothena Reports First Quarter 2026 Financial Results and Business Highlights

Prothena Announces Novo Nordisk Obtains Fast Track Designation from the U.S. FDA for Coramitug (PRX004) in ATTR Amyloidosis with Cardiomyopathy

Prothena Announces Leadership Team Updates

Wall Street Analysts Think Prothena (PRTA) Could Surge 120.19%: Read This Before Placing a Bet

Prothena Partners Present Data Supporting Next Generation Treatments for Parkinson's and Alzheimer's Disease at AD/PD™ 2026

Prothena Announces Achievement of $50 Million Clinical Milestone Payment from Novo Nordisk Related to Ongoing Phase 3 Clinical Trial for Coramitug (Formerly PRX004) in ATTR Amyloidosis with Cardiomyopathy

Videolar

No Data

Press-relizlar

Prothena Reports First Quarter 2026 Financial Results and Business Highlights

Prothena Announces Novo Nordisk Obtains Fast Track Designation from the U.S. FDA for Coramitug (PRX004) in ATTR Amyloidosis with Cardiomyopathy

Prothena Announces Leadership Team Updates

Prothena Partners Present Data Supporting Next Generation Treatments for Parkinson's and Alzheimer's Disease at AD/PD™ 2026